Statin therapy in patients with diastolic heart failure

Clinical Cardiology

Volumn 33, Issue 4, 2010, Pages

  Tehrani, Faramarz ^a   Morrissey, Ryan ^a   Phan, Anita ^a   Chien, Christopher ^a   Schwarz, Ernst R ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC HEART FAILURE; DRUG EFFECT; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; SURVIVAL; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; AGED, 80 AND OVER; FEMALE; HEART FAILURE, DIASTOLIC; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PROPORTIONAL HAZARDS MODELS; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77950792962     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20615     Document Type: Article

References (18)

1. Yamada T, Node K, Mine T, et al. Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study. Am Heart J. 2007;153:1055e1-8
2. Khush KK, Waters DD, Bittner V, et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation. 2007;115:576-583.
3. Domanski M, Coady S, Fleg J, Tian X, Sachdev V. Effect of statin therapy on survival in patients with nonischemic dilated cardiomyopathy (from the β-Blocker Evaluation of Survival Trail [BEST]). Am J Cardiol. 2007;99:1448-1450.
4. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357: 2248-2261.
5. Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation. 2005;112:357-363.
6. Shah R, Wang Y, Foody JM. Effects of statins, angiotensinconverting enzymeinhibitors, and β-blockers on survival in patients =65 years of age with heart failure and preserved left ventricular systolic function. Am J Cardiol. 2008;2:217-222.
7. GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double blind, placebo-controlled trial. Lancet. 2008;Aug 29. [Epub ahead of print].
8. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
9. Collins R, Armitage J, Parish S, Sleight P, Peto R; on behalf of the MRC/BHF Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. Lancet. 2002;360:7-22.
10. Cannon CP, Braunwald E, McCade CH, et al. Intensive versus moderate lipid-lowering with statins after acute coronary syndrome. N Engl J Med. 2004;350:1495-1504.
11. Strippoli GFM, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomized controlled trials. BMJ. 2008; 336:645-651.
12. Tonelli M,Moye L, Sacks FM,Kiberd B, Curhan G. Pravastatinfor secondary prevention of cardiovascularevents in persons withmild chronic renal insufficiency. Ann Intern Med. 2003;138: 98-104.
13. Wisniacki N, Taylor W, Lye M, Wilding JP. Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure. Heart. 2005;91(1):32-37.
14. Mason JM, Freemantle N. Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 199;281:415-419.
15. Okura H, Asawa K, Kubo T, et al. Impact of statin therapy on systemic inflammation, left ventricular systolic and diastolic function and prognosis in low risk ischemic heart disease patients without history of congestive heart failure. InternMed. 2007;46: 1337-1343.
16. Almuti K, Rimawi R, Spevack D, Ostfeld RJ. Effects of statins beyond lipid lowering: potential for clinical benefits. Int J Cardiol. 2006;109:7-15.
17. Xu Z, Okamoto H, Akino M, Onozuka H, Matsui Y, Tsutsui H. Pravastatin attenuates left ventricular remodeling and diastolic dysfunction in angiotensin II-induced hypertensive mice. J Cardiovasc Pharmacol. 2008;51:62-70.
18. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129-1135.